The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bivalirudin Drug Market Research Report 2024
Synopsis
Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a direct thrombin inhibitor (DTI).
The global Bivalirudin Drug market was valued at US$ 596 million in 2023 and is anticipated to reach US$ 887.2 million by 2030, witnessing a CAGR of 6.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Bivalirudin Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bivalirudin Drug.
Report Scope
The Bivalirudin Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bivalirudin Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bivalirudin Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
The Medicines Company
Sandoz
Fresenius Kabi
Pfizer
Mylan
Dr. Reddy's Laboratories
Apotex
Accord Healthcare
Aurobindo Pharma
Segment by Type
Injection
Powder
Segment by Application
Hospital
Drug Store
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bivalirudin Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bivalirudin Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a direct thrombin inhibitor (DTI).
The global Bivalirudin Drug market was valued at US$ 596 million in 2023 and is anticipated to reach US$ 887.2 million by 2030, witnessing a CAGR of 6.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Bivalirudin Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bivalirudin Drug.
Report Scope
The Bivalirudin Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bivalirudin Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bivalirudin Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
The Medicines Company
Sandoz
Fresenius Kabi
Pfizer
Mylan
Dr. Reddy's Laboratories
Apotex
Accord Healthcare
Aurobindo Pharma
Segment by Type
Injection
Powder
Segment by Application
Hospital
Drug Store
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bivalirudin Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bivalirudin Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Bivalirudin Drug Market Overview
1.1 Product Overview and Scope of Bivalirudin Drug
1.2 Bivalirudin Drug Segment by Type
1.2.1 Global Bivalirudin Drug Market Value Comparison by Type (2024-2030)
1.2.2 Injection
1.2.3 Powder
1.3 Bivalirudin Drug Segment by Application
1.3.1 Global Bivalirudin Drug Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Drug Store
1.4 Global Bivalirudin Drug Market Size Estimates and Forecasts
1.4.1 Global Bivalirudin Drug Revenue 2019-2030
1.4.2 Global Bivalirudin Drug Sales 2019-2030
1.4.3 Global Bivalirudin Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Bivalirudin Drug Market Competition by Manufacturers
2.1 Global Bivalirudin Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Bivalirudin Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Bivalirudin Drug Average Price by Manufacturers (2019-2024)
2.4 Global Bivalirudin Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Bivalirudin Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bivalirudin Drug, Product Type & Application
2.7 Bivalirudin Drug Market Competitive Situation and Trends
2.7.1 Bivalirudin Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bivalirudin Drug Players Market Share by Revenue
2.7.3 Global Bivalirudin Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bivalirudin Drug Retrospective Market Scenario by Region
3.1 Global Bivalirudin Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Bivalirudin Drug Global Bivalirudin Drug Sales by Region: 2019-2030
3.2.1 Global Bivalirudin Drug Sales by Region: 2019-2024
3.2.2 Global Bivalirudin Drug Sales by Region: 2025-2030
3.3 Global Bivalirudin Drug Global Bivalirudin Drug Revenue by Region: 2019-2030
3.3.1 Global Bivalirudin Drug Revenue by Region: 2019-2024
3.3.2 Global Bivalirudin Drug Revenue by Region: 2025-2030
3.4 North America Bivalirudin Drug Market Facts & Figures by Country
3.4.1 North America Bivalirudin Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Bivalirudin Drug Sales by Country (2019-2030)
3.4.3 North America Bivalirudin Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Bivalirudin Drug Market Facts & Figures by Country
3.5.1 Europe Bivalirudin Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Bivalirudin Drug Sales by Country (2019-2030)
3.5.3 Europe Bivalirudin Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bivalirudin Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Bivalirudin Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Bivalirudin Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Bivalirudin Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Bivalirudin Drug Market Facts & Figures by Country
3.7.1 Latin America Bivalirudin Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Bivalirudin Drug Sales by Country (2019-2030)
3.7.3 Latin America Bivalirudin Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Bivalirudin Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Bivalirudin Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Bivalirudin Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Bivalirudin Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bivalirudin Drug Sales by Type (2019-2030)
4.1.1 Global Bivalirudin Drug Sales by Type (2019-2024)
4.1.2 Global Bivalirudin Drug Sales by Type (2025-2030)
4.1.3 Global Bivalirudin Drug Sales Market Share by Type (2019-2030)
4.2 Global Bivalirudin Drug Revenue by Type (2019-2030)
4.2.1 Global Bivalirudin Drug Revenue by Type (2019-2024)
4.2.2 Global Bivalirudin Drug Revenue by Type (2025-2030)
4.2.3 Global Bivalirudin Drug Revenue Market Share by Type (2019-2030)
4.3 Global Bivalirudin Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Bivalirudin Drug Sales by Application (2019-2030)
5.1.1 Global Bivalirudin Drug Sales by Application (2019-2024)
5.1.2 Global Bivalirudin Drug Sales by Application (2025-2030)
5.1.3 Global Bivalirudin Drug Sales Market Share by Application (2019-2030)
5.2 Global Bivalirudin Drug Revenue by Application (2019-2030)
5.2.1 Global Bivalirudin Drug Revenue by Application (2019-2024)
5.2.2 Global Bivalirudin Drug Revenue by Application (2025-2030)
5.2.3 Global Bivalirudin Drug Revenue Market Share by Application (2019-2030)
5.3 Global Bivalirudin Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 The Medicines Company
6.1.1 The Medicines Company Corporation Information
6.1.2 The Medicines Company Description and Business Overview
6.1.3 The Medicines Company Bivalirudin Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 The Medicines Company Bivalirudin Drug Product Portfolio
6.1.5 The Medicines Company Recent Developments/Updates
6.2 Sandoz
6.2.1 Sandoz Corporation Information
6.2.2 Sandoz Description and Business Overview
6.2.3 Sandoz Bivalirudin Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sandoz Bivalirudin Drug Product Portfolio
6.2.5 Sandoz Recent Developments/Updates
6.3 Fresenius Kabi
6.3.1 Fresenius Kabi Corporation Information
6.3.2 Fresenius Kabi Description and Business Overview
6.3.3 Fresenius Kabi Bivalirudin Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Fresenius Kabi Bivalirudin Drug Product Portfolio
6.3.5 Fresenius Kabi Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Bivalirudin Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Bivalirudin Drug Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Mylan
6.5.1 Mylan Corporation Information
6.5.2 Mylan Description and Business Overview
6.5.3 Mylan Bivalirudin Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Mylan Bivalirudin Drug Product Portfolio
6.5.5 Mylan Recent Developments/Updates
6.6 Dr. Reddy's Laboratories
6.6.1 Dr. Reddy's Laboratories Corporation Information
6.6.2 Dr. Reddy's Laboratories Description and Business Overview
6.6.3 Dr. Reddy's Laboratories Bivalirudin Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Dr. Reddy's Laboratories Bivalirudin Drug Product Portfolio
6.6.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.7 Apotex
6.6.1 Apotex Corporation Information
6.6.2 Apotex Description and Business Overview
6.6.3 Apotex Bivalirudin Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Apotex Bivalirudin Drug Product Portfolio
6.7.5 Apotex Recent Developments/Updates
6.8 Accord Healthcare
6.8.1 Accord Healthcare Corporation Information
6.8.2 Accord Healthcare Description and Business Overview
6.8.3 Accord Healthcare Bivalirudin Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Accord Healthcare Bivalirudin Drug Product Portfolio
6.8.5 Accord Healthcare Recent Developments/Updates
6.9 Aurobindo Pharma
6.9.1 Aurobindo Pharma Corporation Information
6.9.2 Aurobindo Pharma Description and Business Overview
6.9.3 Aurobindo Pharma Bivalirudin Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Aurobindo Pharma Bivalirudin Drug Product Portfolio
6.9.5 Aurobindo Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bivalirudin Drug Industry Chain Analysis
7.2 Bivalirudin Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bivalirudin Drug Production Mode & Process
7.4 Bivalirudin Drug Sales and Marketing
7.4.1 Bivalirudin Drug Sales Channels
7.4.2 Bivalirudin Drug Distributors
7.5 Bivalirudin Drug Customers
8 Bivalirudin Drug Market Dynamics
8.1 Bivalirudin Drug Industry Trends
8.2 Bivalirudin Drug Market Drivers
8.3 Bivalirudin Drug Market Challenges
8.4 Bivalirudin Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
